Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia

Blood

Volumn 93, Issue 9, 1999, Pages 3074-3080

  Kiyoi, Hitoshi ^b   Naoe, Tomoki ^a   Nakano, Yasuyuki ^b   Yokota, Shohei ^b   Minami, Saburo ^b   Miyawaki, Shuichi ^b   Asou, Norio ^b   Kuriyama, Kazutaka ^b   Jinnai, Itsuro ^b   Shimazaki, Chihiro ^b   Akiyama, Hideki ^b   Saito, Kenji ^b   Oh, Hakumei ^b   Motoji, Toshiko ^b   Omoto, Eijiro ^b   Saito, Hidehiko ^b   Ohno, Ryuzo ^b   Ueda, Ryuzo ^b  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE N RAS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENES, RAS; HUMANS; LEUKEMIA, MYELOID; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENES; RECEPTOR PROTEIN-TYROSINE KINASES; REMISSION INDUCTION; SURVIVAL RATE;

EID: 0033134792     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Mrózek K, Heinonen K, de la Chapelle A, Bloomfield CD: Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 24:17, 1997
2. Caligiuri MA, Strout MP, Gilliland DG: Molecular biology of acute myeloid leukemia. Semin Oncol 24:32, 1997
3. Look AT: Oncogenic transcription factors in the human acute leukemias. Science 278:1059, 1997
4. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148, 1994
5. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855, 1994
6. Bos JL: Ras oncogenes in human cancer: A review. Cancer Res 49:4682, 1989
7. Radich JP, Kopecky KJ, Willman CL, Weick J, Head D, Appelbaum F, Collins SJ: N-ras mutations in adult de novo acute myelogenous leukemia: Prevalence and clinical significance. Blood 76:801, 1990
8. Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, Schiffer CA, Mayer RJ, Ball ED, Wurster-Hill D, Bloomfield CD, Liu ET: Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 83:1603, 1994
9. Kubo K, Naoe T, Kiyoi H, Fukutani H, Kato Y, Oguri T, Yamamori S, Akatsuka Y, Kodera Y, Ohno R: Clonal analysis of multiple point mutations in the N-ras gene in patients with acute myeloid leukemia. Jpn J Cancer Res 84:379, 1993
10. Nakao H, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, Misawa S: Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10:1911, 1996
11. Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, Sonoda Y, Abe T, Kashima K, Matsuo Y, Naoe T: Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11:1605, 1997
12. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR: A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 65:1143, 1991
13. Rosnet O, Schiff C, Pébusque MJ, Marchetto S, Tonnelle C, Toiron Y, Birg F, Birnbaum D: Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 82:1110, 1993
14. Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, Witte L, Burrow C, Ratajczak MZ, Gewirtz AM, Civin CI: STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 91:459, 1994
15. Lyman SD, Jacobsen SEW: c-kit ligand and Flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities. Blood 91:1101, 1998
16. Drexler HG: Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 10:588, 1996
17. Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H, Naoe T: Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12:1333, 1998
18. Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K, Takeshita A, Saito K, Hasegawa S, Shimodaira S, Tamura J, Shimazaki C, Matsue K, Kobayashi H, Arima N, Suzuki R, Morishita H, Saito H, Ueda R, Ohno R: Internal tandem duplication of FLT3 associated with leucocytosis in acute promyelocytic leukemia. Leukemia 11:1447, 1997
19. Ohno R, Kobayashi T, Tanimoto M, Hiraoka A, Imai K, Asou N, Tomonaga M, Tsubaki K, Takahashi I, Kodera Y, Yoshida M, Murakami H, Naoe T, Shimoyama M, TsukadaT, Takeo T, Teshima H, Onozawa Y, Fujimoto K, Kuriyama K, Horiuchi A, Kimura I, Minami S, Miura Y, Kageyama S, Tahara T, Masaoka T, Shirakawa S, Saito H: Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group. Cancer 71:3888, 1993
20. Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, Minami S, Minato K, Tsubaki K, Ohmoto E, Oh H, Jinnai I, Sakamaki H, Hiraoka A, Kanamaru A, Takahashi I, Saito K, Naoe T, Yamada O, Asou N, Kageyama S, Emi N, Matsuoka A, Tomonaga M, Saito H, Ueda R, Ohno R: Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/ intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol 14:204, 1996
21. Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Hatake K, Kuriyama K, Ohmoto E, Saito K, Kanamaru A, Oho H, Ohtake S, Jinnai I, Sakamaki H, Yamada O, Asou N, Takahashi M, Takeyama K, Matsuda S, Ueda R, Ohno R: Randomized study of individualized induction therapy with or without etoposide in adult acute myeloid leukemia (except for M3) (JALSG-AML92 study) and analysis of prognostic factors. Blood 90:503a, 1997 (abstr, suppl 1)
22. Bradstock K, Matthews J, Benson E, Page F, Bishop J: Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood 84:1220, 1994
23. Bishop JF: The treatment of adult acute myeloid leukemia. Semin Oncol 24:57, 1997
24. Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, Sakamaki H, Tsubaki K, Hiraoka A, Yamada O, Oh H, Saito K, Matsuda S, Minato K, Ueda T, Ohno R: All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 85:1202, 1995
25. Lisovsky M, Estrov Z, Zhang X, Consoli U, Sanchez-Williams G, Snell V, Munker R, Goodacre A, Savchenko V, Andreeff M: Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: Regulation of Bcl-2 and Bax. Blood 88:3987, 1996
26. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, Wagenaar SS, Vanderschueren RG, van Zandwijk N, Mooi WJ, Bos JL, Rodenhuis S: K-RAS oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561, 1990
27. Lübbert M, Mirro J Jr, Miller CW, Kahan J, Issac G, Kitchingman G, Mertelsmann R, Herrmann F, McCormick F, Koeffler HP: N-Ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood 75:1163, 1990
28. Gordon MY, Goldman JM: Cellular and molecular mechanisms in chronic myeloid leukaemia: Biology and treatment. Br J Haematol 95:10, 1996
29. Lavagna-Sevenier C, Marchetto S, Birnbaum D, Rosnet O: FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia 12: 301, 1998
30. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM: Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379:645, 1996